28.11.2013 07:49
Bewerten
(0)

Press Release: Novartis: New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle

DRUCKEN
-1 of 2- 28 Nov 2013 06:16:00 UTC  *DJ Novartis: New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle

   (MORE TO FOLLOW) Dow Jones Newswires

   November 28, 2013 01:16 ET (06:16 GMT)- - 01 16 AM EST 11-28-13

-2 of 2- 28 Nov 2013 06:16:00 UTC  Press Release: Novartis: New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle

Novartis International AG / New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

-- Findings published in Nature advance a Novartis goal to help eliminate malaria by identifying a new target that could lead to a treatment for multiple stages of the disease

-- Malaria kills more than 660,000 people each year, mostly African children[1]

Basel, Switzerland, November 28, 2013 - Novartis scientists have discovered a new drug target for treating malaria. The discovery, which is published online in the journal Nature,[2] identifies phosphatidylinositol-4 kinase (PfPI4K) as the target of the imidazopyrazines, a novel experimental antimalarial compound class that inhibits the development of multiple malaria-causing Plasmodium species at each stage of infection in the human host.

The on-going research to develop imidazopyrazines as a new treatment for malaria is supported by the Wellcome Trust and Medicines for Malaria Venture.

Each year malaria kills more than 660,000 people most of whom are African children. While current therapies are effective against the most common forms of malaria, recent publications suggest that the efficacy of the artemisinin-derivatives has been compromised in parts of South-East Asia. In addition, these therapies are only effective against the acute blood stages of the disease, thus leaving some patients at risk of relapse after initial treatment. Relapse prevention is especially important for P. vivax, which can form hypnozoites, dormant parasites that can persist in the liver for up to two years before reinitiating a blood-stage infection.

"This new target for malaria provides an avenue to develop the next-generation antimalarial drugs that are capable of preventing, treating and blocking the spread of malaria, a key goal of Novartis," commented Thierry Diagana, Head of the Novartis Institute for Tropical Diseases. "Compounds that inhibit this new target have the potential to complement our current malaria drug pipeline, KAE609 and KAF156, and could provide a path toward elimination of the disease."

The paper describes how scientists discovered a new class of compound with an imidazopyrazine core, to identify this new malaria target. "Our scientists carried out a large phenotypic screen which, coupled with modern genome analysis and editing tools, constitute a powerful technology platform to discover and validate drug targets for next-generation antimalarial drug discovery," said Martin Seidel, Institute Director of the Genomics Institute of the Novartis Research Foundation (GNF).

They then isolated strains of parasites that had become resistant to the compound class and identified the mutated genes. For one of these genes, PfPI4K, they went on to show through biochemical experiments that imidazopyrazines work through interaction with the ATP-binding pocket of the kinase. They also showed that these compounds are active against blood-stage field isolates of the major human malaria pathogens, P. falciparum and P. vivax, and inhibit liver-stage hypnozoites of a parasite P. cynomolgi, which is closely related to P. vivax.

Scientists from GNF and NITD collaborated with an international team of scientists from the University of California, San Diego, and Columbia University.

Broader commitment to fighting malaria: Novartis Malaria Initiative

This research is part of a broader commitment by Novartis and complements our current malaria drug pipeline, KAE609 and KAF156, in the fight against malaria. The Novartis Malaria Initiative is one of the pharmaceutical industry's largest access-to-medicines programs, focused on treatment, access, capacity-building and research & development. Over the last decade, the initiative has delivered over 600 million treatments without profit to the public sector, in more than 60 countries. Novartis believes that increasing access to medicines in developing countries is not just a matter of buying medicines and distributing them, it also requires bringing together good clinical practice, logistics management and other expertise to ensure a long-term sustainable approach to improving health. For more information visit www.malaria.novartis.com.

Disclaimer

This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "potential," "goal," "could," "experimental," "commitment," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in all these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References

[1] World Health Organization, http://www.who.int/mediacentre/factsheets/fs094/en/

[2] http://dx.doi.org/10.1038/nature12782. (live when embargo lifts)

# # #

Novartis Media Relations

Central media line : +41 61 324 2200 Anja von Treskow Mariellen Gallagher Novartis Global Media Relations Novartis Institutes for BioMedical Research +41 61 324 8137 (direct) +1 617 871 7665 (direct) +41 79 367 4723 (mobile) +1 617 909 9137 (mobile) anja.von_treskow@novartis.com mariellen.gallagher@novartis.com

e-mail: media.relations@novartis.com

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis

For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com

Novartis Investor Relations

Central phone: +41 61 324 7944 Samir Shah +41 61 324 7944 North America: Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301 Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445 Isabella Zinck +41 61 324 7188 Susanne Donofrio +1 862 778 9257

e-mail: investor.relations@novartis.com

Media release (PDF): http://hugin.info/134323/R/1746248/587824.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via Globenewswire

HUG#1746248

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com (END) Dow Jones Newswires

   November 28, 2013 01:16 ET (06:16 GMT)- - 01 16 AM EST 11-28-13

Nachrichten zu Novartis AG (Spons. ADRS)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Novartis AG (Spons. ADRS)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
10.11.2016Novartis BuyArgus Research Company
10.10.2016Novartis BuyChardan Capital Markets
20.09.2016Novartis BuyChardan Capital Markets
01.03.2013Novartis verkaufenVontobel Research
29.01.2013Novartis haltenHamburger Sparkasse AG (Haspa)
10.11.2016Novartis BuyArgus Research Company
10.10.2016Novartis BuyChardan Capital Markets
20.09.2016Novartis BuyChardan Capital Markets
06.01.2010Novartis "buy"SEB AG
22.10.2009Novartis buySEB AG
29.01.2013Novartis haltenHamburger Sparkasse AG (Haspa)
24.01.2013Novartis haltenFrankfurter Tagesdienst
01.03.2013Novartis verkaufenVontobel Research
24.01.2013Novartis verkaufenVontobel Research
23.01.2013Novartis verkaufenVontobel Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG (Spons. ADRS) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Webinar: Der große Ausblick auf 2018!

Am 13. Dezember gibt Simon Betschinger von TraderFox im Anlegerclub der Börse Stuttgart einen Ausblick auf das kommende Börsenjahr. Dabei nimmt er ausgewählte Aktien unter die Lupe und erklärt, warum er genau diese Werte für besonders aussichtsreich hält.
Jetzt kostenfrei registrieren
und dabei sein!

Novartis Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX geht fester ins Wochenende -- US-Börsen schließt im Plus -- Bitcoin-Handel: Massive technische Probleme vor Future-Start -- Moody's stuft Steinhoff auf Ramsch ab -- VW im Fokus

Qiagen steigert Marge. Bayer muss mit Auflagen rechnen. Apple bringt seine TV-App nach Deutschland. Bankentitel im Höhenflug nach erstem Brexit-Erfolg. Swiss Re bekommt 2018 neuen CFO und verkleinert Geschäftsführung. Goldman Sachs will offenbar Bitcoin-Futures abwickeln. US-Kongress vermeidet 'Shutdown' für zunächst zwei Wochen.

Top-Rankings

KW 49: Analysten-Tops der Woche
Diese Aktien stehen auf den Kauflisten der Experten
Weihnachtsgeld 2017
Wer bekommt wo wieviel?
Die beliebtesten Weihnachtsgeschenke 2017
Welches Geschenk liegt am häufigsten unter dem Baum?

Die 5 beliebtesten Top-Rankings

Siebenstelliges Jahresgehalt
In diesen Bundesländern leben die Bestverdiener
Das sind die größten Privatbanken weltweit
Welche Bank macht 2017 das Rennen?
Renteneintrittsalter
Hier arbeiten die Menschen am längsten
Die Länder mit den größten Goldreserven 2017
Wo lagert das meiste Gold?
Diese Aktien hat Warren Buffett im Depot
Neuer Platz Eins
mehr Top Rankings

Umfrage

Glauben Sie, dass es in den kommenden sechs Monaten schwieriger wird, die eigenen Renditeerwartungen zu erzielen?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Volkswagen (VW) AG Vz.766403
Steinhoff International N.V.A14XB9
Scout24 AGA12DM8
Daimler AG710000
BMW AG519000
Apple Inc.865985
BASFBASF11
Allianz840400
EVOTEC AG566480
E.ON SEENAG99
Bitcoin Group SEA1TNV9
Amazon906866
CommerzbankCBK100
adidas AGA1EWWW